- Datum03.02.2026
- Uhrzeit12:00 - 13:00 Uhr
- Veranstalter
stock3
Candel Therapeutics Chart inkl. Chartanalyse
Charts analysieren
wie die Profis?
Nutze unser Profi-Charting-Tool für Deine eigenen Analysen
Chart analysieren
Candel Therapeutics Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Société Générale | VK | |||||
| Nasdaq | VK | |||||
| Nasdaq Basic | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-0,95 %
Intraday
-2,45 %
1 Woche
6,35 %
1 Monat
10,49 %
Seit Jahresbeginn
-11,57 %
1 Jahr
129,52 %
3 Jahre
Passender Service zu Candel Therapeutics
Webinar zu Candel Therapeutics
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)4,250-13,680
- Jahrestief / Hoch ($)---
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Candel Therapeutics
Keine Dividenden verfügbar
Termine von Candel Therapeutics
Keine aktuellen Termine
Beschreibung
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
